Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PARPi focus the spotlight on replication fork protection in cancer

PARP inhibitors (PARPi) kill BRCA1/2-mutated cancers, which become resistant when DNA repair functions are restored. Now, MUS81 nuclease inhibition due to EZH2 downregulation is found to restore DNA replication fork protection but not repair, leading to PARPi-resistance in mutant BRCA2 cells and patients. This challenges the DNA repair dominance in synthetic lethality.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mechanisms for PARPi resistance.

References

  1. Helleday, T. Mol. Oncol. 5, 387–393 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Berti, M. et al. Nat. Struct. Mol. Biol. 20, 347–354 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Schlacher, K. et al. Cell 145, 529–542 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Schlacher, K., Wu, H. & Jasin, M. Cancer Cell 22, 106–116 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wang, A. T. et al. Mol. Cell 59, 478–490 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ying, S., Hamdy, F. C. & Helleday, T. Cancer Res. 72, 2814–2821 (2012).

    Article  CAS  PubMed  Google Scholar 

  7. Rondinelli, B. et al. Nat. Cell Biol. 1371–1378 (2017).

  8. Lemaçon, D. et al. Nat. Commun. https://doi.org/10.1038/s41467-017-01180–5 (2017).

  9. Mijic, S. et al. Nat. Commun. https://doi.org/10.1038/s41467-017-01164–5 (2017).

  10. Kolinjivadi, A. M. et al. Mol. Cell 67, 867–881 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Dungrawala, H. et al. Mol. Cell 67, 374–386 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ray Chaudhuri, A. et al. Nature 535, 382–387 (2016).

    Article  PubMed  Google Scholar 

  13. Sakai, W. et al. Nature 451, 1116–1120 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bunting, S. F. et al. Cell 141, 243–254 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Katharina Schlacher.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schlacher, K. PARPi focus the spotlight on replication fork protection in cancer. Nat Cell Biol 19, 1309–1310 (2017). https://doi.org/10.1038/ncb3638

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncb3638

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer